ArticlePharmacogenomics2013
Assessment of a pharmacogenomic marker panel in a polypharmacy population identified from electronic medical records.
Article in Pharmacogenomics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- The Value of Pharmacogenetics to Reduce Drug-Related Toxicity in Cancer Patients.Molecular diagnosis & therapy · 2022Article
- ThePharmacogenomics and personalized medicine · 2022Article
- Validation of a Large Custom-Designed Pharmacogenomics Panel on an Array Genotyping Platform.The journal of applied laboratory medicine · 2021Article
- Precision Pharmacotherapy: Integrating Pharmacogenomics into Clinical Pharmacy Practice.Journal of the American College of Clinical Pharmacy : JACCP · 2019Article
- Emerging Role of Precision Medicine in Cardiovascular Disease.Circulation research · 2018Review
- Implementation of inpatient models of pharmacogenetics programs.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2016Review
- Minimum information required for a DMET experiment reporting.Pharmacogenomics · 2016Article
- Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network.Clinical pharmacology and therapeutics · 2016Article
- Evidence for extensive pleiotropy among pharmacogenes.Pharmacogenomics · 2016Article
- Potential utility of precision medicine for older adults with polypharmacy: a case series study.Pharmacogenomics and personalized medicine · 2016Article
- THE CHALLENGES IN USING ELECTRONIC HEALTH RECORDS FOR PHARMACOGENOMICS AND PRECISION MEDICINE RESEARCH.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2016Article
- Pharmacogenetic polymorphism as an independent risk factor for frequent hospitalizations in older adults with polypharmacy: a pilot study.Pharmacogenomics and personalized medicine · 2016Article
- Pharmacogenomics in the clinic.Nature · 2015Review
- Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers.Annual review of pharmacology and toxicology · 2015Review
- Elements for adequate informed consent in the surgical context.World journal of surgery · 2014Article
- Utilization of an EMR-biorepository to identify the genetic predictors of calcineurin-inhibitor toxicity in heart transplant recipients.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundThe ADME Core Panel assays 184 variants across 34 pharmacogenes, many of which are difficult to accurately genotype with standard multiplexing methods.
methodsWe genotyped 326 frequently medicated individuals of European descent in Vanderbilt's biorepository linked to de-identified electronic medical records, BioVU, on the ADME Core Panel to assess quality and performance of the assay. We compared quality control metrics and determined the extent of direct and indirect marker overlap between the ADME Core Panel and the Illumina Omni1-Quad.
resultsWe found the quality of the ADME Core Panel data to be high, with exceptions in select copy number variants and markers in certain genes (notably CYP2D6). Most of the common variants on the ADME panel are genotyped by the Omni1, but absent rare variants and copy number variants could not be accurately tagged by single markers.
conclusionOur frequently medicated study population did not convincingly differ in allele frequency from reference populations, suggesting that heterogeneous clinical samples (with respect to medications) have similar allele frequency distributions in pharmacogenetics genes compared with reference populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.